Regeneron Pharmaceuticals Inc. buy BMO Capital Markets
Summary
This prediction is currently active. With a performance of -4.43%, the BUY prediction by BMO_Capital_Markets is trending in the wrong direction. Dividends of €0.88 are taken into consideration when calculating the performance. This prediction currently runs until 30.04.26. The prediction end date can be changed by BMO_Capital_Markets at any time. BMO_Capital_Markets has 50% into this predictionRegeneron Pharmaceuticals, Inc. is a biotechnology company that is engaged in the discovery, development, and commercialization of medicines for the treatment of serious medical conditions. The company's products include EYLEA, a treatment for wet age-related macular degeneration and diabetic macular edema; Dupixent, a treatment for atopic dermatitis and asthma; and Libtayo, a treatment for certain types of cancer. Regeneron also has a strong focus on research and development, with a pipeline of potential new treatments for a variety of diseases. The company is headquartered in Tarrytown, New York and trades on the NASDAQ stock exchange under the symbol REGN.
Performance without dividends (%)
Name | 1w | 1m |
---|---|---|
Regeneron Pharmaceuticals Inc. | 2.606% | 2.606% |
iShares Core DAX® | 0.648% | -0.148% |
iShares Nasdaq 100 | -0.034% | 1.859% |
iShares Nikkei 225® | 2.445% | 8.129% |
iShares S&P 500 | 0.492% | 1.525% |
Comments by BMO_Capital_Markets for this prediction
In the thread Regeneron Pharmaceuticals Inc. diskutieren
Stopped prediction by BMO_Capital_Markets for Regeneron Pharmaceuticals Inc.
Regeneron Pharmaceuticals Inc.
04.08.25
04.08.26
22:26
Regeneron Pharmaceuticals Inc.
02.06.25
02.06.26
22:26
Regeneron Pharmaceuticals Inc.
04.02.25
04.02.26
22:26
Regeneron Pharmaceuticals Inc.
01.11.24
01.11.25
22:26
Regeneron Pharmaceuticals Inc.
24.09.24
24.09.25
22:26
Regeneron Pharmaceuticals Inc.
05.02.24
05.02.25
06.02.25